FDMT 4D Molecular Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FDMT

Price (delayed)

$15

Market cap

$828.66M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.63

Enterprise value

$797.51M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 35
Highlights
The gross profit has increased by 4.3% since the previous quarter
FDMT's revenue is up by 4.3% since the previous quarter
4D Molecular Therapeutics's EPS has increased by 25% YoY but it has decreased by 2.3% from the previous quarter
The company's net income fell by 11% QoQ but it rose by 9% YoY
The company's debt has surged by 91% QoQ and by 70% YoY
FDMT's quick ratio is down by 15% QoQ and by 9% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of FDMT

FDMT stock price

How has the 4D Molecular Therapeutics stock price performed over time
Intraday
-5.54%
1 week
9.01%
1 month
-5.24%
1 year
97.11%
YTD
100%
QTD
12.78%

Financial performance

How have 4D Molecular Therapeutics's revenue and profit performed over time
Revenue
$92.01M
Gross profit
$92.01M
Operating income
-$197.12M
Net income
-$179.18M
Gross margin
100%
Net margin
-194.7%
The operating margin has soared by 100% YoY but it has contracted by 5% from the previous quarter
The company's net margin has surged by 100% YoY but it fell by 7% QoQ
The company's net income fell by 11% QoQ but it rose by 9% YoY
The operating income is up by 11% YoY but it is down by 10% QoQ

Price vs fundamentals

How does FDMT's price correlate with its fundamentals

Growth

What is 4D Molecular Therapeutics's growth rate over time

Valuation

What is 4D Molecular Therapeutics stock price valuation
P/E
N/A
P/B
1.92
P/S
11.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.67
4D Molecular Therapeutics's EPS has increased by 25% YoY but it has decreased by 2.3% from the previous quarter
The stock's P/B is 70% above its last 4 quarters average of 1.2 and 28% above its 5-year quarterly average of 1.6
The company's equity fell by 10% QoQ and by 3.1% YoY
The P/S is 100% lower than the 5-year quarterly average of 3147.5 and 99% lower than the last 4 quarters average of 1021.7
FDMT's revenue is up by 4.3% since the previous quarter

Efficiency

How efficient is 4D Molecular Therapeutics business performance
4D Molecular Therapeutics's ROS has soared by 100% YoY but it has decreased by 7% from the previous quarter
The return on invested capital rose by 14% year-on-year but it has declined by 9% since the previous quarter
The return on equity has declined by 12% since the previous quarter and by 3% year-on-year
The ROA has contracted by 10% from the previous quarter

Dividends

What is FDMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FDMT.

Financial health

How did 4D Molecular Therapeutics financials performed over time
The total liabilities has soared by 61% YoY and by 39% from the previous quarter
FDMT's quick ratio is down by 15% QoQ and by 9% YoY
The company's debt is 90% lower than its equity
FDMT's debt to equity has surged by 100% since the previous quarter and by 100% year-on-year
The company's debt has surged by 91% QoQ and by 70% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.